“…There is much debate about the most efficient way to identify new compounds with activity against Mycobacterium tuberculosis; the description of the M. tuberculosis genome in 1998 opened the door for rational drug design and a targeted approach to key metabolic pathways (Cole et al, 1998;Sams-Dodd, 2005). Alternative strategies include screening compound libraries, whether synthetically produced derivatives (Guzman et al, 2011) or natural compounds derived from plants (Guzman et al, 2012;Guzman et al, 2010;O'Donnell et al, 2009;Osman et al, 2012) or lower order animals such as the marine sponges (Kottakota et al, 2012a;Kottakota et al, 2012b;Sim et al, 2008). These combined approaches have yielded some hits, but progress is slow and so the idea of revisiting and repurposing drugs previously ruled out for treatment of tuberculosis but in use for other disease presentations has gained traction.…”